Half-Matched hope: new stem cell approach for sickle cell disease enters human testing

NCT ID NCT03279094

Recruiting now Disease control Sponsor: City of Hope Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tests a new approach to stem cell transplants for sickle cell disease. It uses a half-matched (haploidentical) donor, which could help more patients find a donor. Before the transplant, patients receive two cycles of immune-suppressing therapy to prepare their body. The main goal is to see if this approach is safe and tolerable.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Haploidentical stem cell transplant with pre-transplant immunosuppression
What this could lead to: If successful, this could expand the donor pool for sickle cell patients, making stem cell transplants available to more people who lack a fully matched donor.
What could go wrong: This is a very early Phase 1 trial with only 11 participants, focused on safety. The regimen is intense and carries risks like graft failure, severe side effects, or death. Success is far from guaranteed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SICKLE CELL DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

sickle cell disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SICKLE CELL DISEASE

Contacts and locations

Locations

City of Hope Medical Center
RECRUITING

Duarte, California, 91010, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.